Partnership for the U.S. Life Science Ecosystem to raise awareness on importance of mergers and acquisitions in advancing future cures and treatments

WASHINGTON, D.C. – More than thirty leading organizations from across the life sciences today launched the Partnership for the U.S. Life Science Ecosystem (PULSE), a coalition to raise awareness of the fundamental role of pro-innovation mergers and acquisitions (M&A) in advancing the next generation of treatments and cures for patients.

PULSE logo

The U.S. is home to thousands of life sciences and biopharmaceutical companies, comprising one of the most diverse and highly competitive industries worldwide. Life sciences companies of all sizes engage in M&A to achieve broad, efficient allocation of resources and expertise that are essential to stay in operation and navigate the complex regulatory, reimbursement and distribution systems within the biopharmaceutical market. Pro-innovation M&A offers an indispensable bridge that helps shepherd early discoveries into the lifesaving treatments and cures needed for patients.

Policymakers, regulators and the courts have long recognized the unique aspects of the life sciences industry, including the differentiated and vital role that pro-innovation M&A plays within it. On average, it takes 10-15 years and costs $2.6 billion to develop and bring a new medicine to patients, including the cost of the many failures along the way. Only 12 percent of new molecular entities that enter clinical trials eventually receive U.S. Food and Drug Administration (FDA) approval.

Even when a medicine or treatment receives regulatory approval, the competition that exists – between innovative products already on the market, emerging new therapies in development and, eventually generic and biosimilar competition – all contribute to America’s life sciences ecosystem being one of the most competitive industries in the world.

Recently, the Federal Trade Commission (FTC) articulated a new approach to antitrust enforcement that runs counter to long-standing precedent that has guided pro-innovation M&A for decades. If continued, the FTC’s flawed approach to M&A review and enforcement would undermine the dynamic ecosystem responsible for many of the world’s most innovative and important treatments. Deterring pro-innovation M&A would obstruct the many complementary relationships across the life sciences ecosystem, stalling treatments and cures for patients while risking jobs, wages and economic growth in every state.

PULSE members – representing frontline researchers, employees, and leaders of life sciences companies of all sizes – will collectively highlight the importance of shared efficiencies and expertise that companies leverage across the development process through M&A to make sure patients receive lifesaving treatments as quickly as possible. PULSE members will also provide real-world insight into the economic importance and benefits of M&A within local communities and to broader growth and development.

A full list of partners is included here pulseforinnovation.org/partners.

“When you consider the various milestones where M&A is so vital to a medicine’s discovery, development and distribution, it becomes all the more imperative that policymakers recognize the importance and immediacy in protecting these pro-innovation partnerships,” Joan Koerber-Walker, President and CEO of AZBio , said. “In Arizona, we have multiple examples where two companies have come together.  The combined firms were able to leverage increased operational efficiencies and reach more patients as they brought their health innovation to market. The positive impacts are measurable in job creation and economic growth. And, best of all, more patients here in Arizona and around the world, are reaping the benefits.”

“Colorado’s growing life sciences community, recently ranked 8th in the country by JLL, makes important contributions to the state’s economy,” said Elyse Blazevich, President & CEO of Colorado BioScience Association . “Mergers and acquisitions support our state’s health innovators working to bring breakthroughs from the lab bench to a patient’s bedside.  We find that acquired companies often retain a foothold in our state because of our top talent and quality of life.” 

“The vast majority of life sciences companies are small businesses, and the ability to grow, innovate and consistently scale relies on M&A,” Karen Kerrigan, President and CEO of the Small Business & Entrepreneurship Council , said. “Policymakers and regulators should take great caution in adopting antitrust policies that pose a fundamental disruption to the very essence of partnership that brings patients the innovative and breakthrough medicines they need.”

More information, including on how to become a partner with PULSE, can be found at pulseforinnovation.org.

###

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: